Enzo Biochem Inc. ENZ announced that its Enzo Clinical Labs subsidiary has reached an agreement with IncellDx Inc. of Menlo Park, CA, for the rights to market a proprietary laboratory test.
The test is based upon HPV OncoTect™, an advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer and will further expand Enzo's approach to providing comprehensive clinical information to physicians for managing diseases associated with women's health.
Upon receiving the appropriate approvals, Enzo will become the first New York licensed reference laboratory to offer the test.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in